NCT02184039已完成不适用
Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12,687
- 主要终点
- Change in intensity of the symptoms measured with a four-point scale
研究概览
简要总结
Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Hypersensitivity to meloxicam or to other NSAIDS
- •History of asthma, angioedema or urticaria secondary to NSAIDS
- •Pregnancy or lactation
- •Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure
- •Age below of 12 years.
结局指标
主要结局
Change in intensity of the symptoms measured with a four-point scale
时间窗: Baseline, 30 and 90 days
次要结局
- Degree of satisfaction evaluated with a six point numerical rating scale(up to 90 days)
- Number of patients with adverse events(up to 90 days)
研究者
相似试验
已完成
不适用
Observational Study of Meloxicam in Mexican Patients With Rheumatic DiseasesArthritis, RheumatoidNCT02184065Boehringer Ingelheim22,639
已完成
4 期
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or LaryngitisPharyngitisNCT02229747Boehringer Ingelheim128
已完成
2 期
Meloxicam vs Placebo for MobilizationNon-Hodgkin's LymphomaHodgkin's LymphomaHematopoietic Stem CellsMultiple MyelomaNCT02003625Massachusetts General Hospital31
已完成
3 期
A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With OsteoarthritisOsteoarthritisNCT00239395Boehringer Ingelheim168
已完成
3 期
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing SpondylitisSpondylitis, AnkylosingNCT02183168Boehringer Ingelheim192